PURPOSE: ABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines. METHODS: The cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay. RESULTS: TPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX. CONCLUSION: The results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2.
PURPOSE:ABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines. METHODS: The cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay. RESULTS:TPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX. CONCLUSION: The results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2.
Authors: Víctor Vital-Reyes; Cristina Rodríguez-Burford; David C Chhieng; Denise K Oelschlager; Alejandro Reyes-Fuentes; Mack Barnes; William E Grizzle Journal: Arch Med Res Date: 2006-08 Impact factor: 2.235
Authors: Maria Chiara Zatelli; Andrea Luchin; Federico Tagliati; Stefania Leoni; Daniela Piccin; Marta Bondanelli; Roberta Rossi; Ettore C degli Uberti Journal: Endocr Relat Cancer Date: 2007-12 Impact factor: 5.678
Authors: Clifford W Mason; Gene T Lee; Yafeng Dong; Helen Zhou; Lily He; Carl P Weiner Journal: Drug Metab Dispos Date: 2014-09-26 Impact factor: 3.922
Authors: Samikkannu Thangavel; Carmen T Mulet; Venkata S R Atluri; Marisela Agudelo; Rhonda Rosenberg; Jessy G Devieux; Madhavan P N Nair Journal: Antioxid Redox Signal Date: 2018-02-01 Impact factor: 8.401
Authors: Mahbuba Rahman; Krithika Selvarajan; Mohammad R Hasan; Annie P Chan; Chaoyang Jin; Jieun Kim; Simon K Chan; Nhu D Le; Young-Bae Kim; Isabella T Tai Journal: Neoplasia Date: 2012-07 Impact factor: 5.715